IBRX - ImmunityBio: All Eyes On Execution Now (Rating Upgrade)

2024-07-08 23:23:13 ET

Summary

• ImmunityBio has seen success with its first drug approval for bladder cancer, Anktiva, and positive results in lung cancer trials.
• Financially, the company has a weak cash position but the potential for significant sales with Anktiva, leading to a $4 billion valuation.
• Investor dedication and high short interest create volatility and potential for a short squeeze, making IBRX a unique investment opportunity.

Topline Summary and Update

ImmunityBio ( IBRX ) has been a fascinating story to watch, coming about as close to "meme stock" as we have seen in the biotech space due to the convergence of a highly dedicated shareholder base, successful clinical execution, massive short interest, and a CEO who has been unusually accountable and responsible for the operations of the company....

For further details see: